Elvitegravir
VITEKTA
What it isHIV integrase strand transfer inhibitor; part of a boosted single-tablet regimen.
Why this oneOnce daily in a complete tablet.
What limits itIt requires cobicistat boosting, which brings CYP3A4 interactions and a lower resistance barrier than dolutegravir or bictegravir.
FDA-approved for
- HIV-1 infection (boosted, in fixed-dose combination) (2012)
NO BOXED WARNINGS
Principal riskCobicistat boosting brings CYP3A4 interactions
Classes and tags
Clinical profile
Mechanism of action: Elvitegravir ballicule
